ABSTRACT
The addition of 5 days of rifampin therapy to a 10- or 14-day course of penicillin or erythromycin therapy has been shown to reduce greatly the rate of chronic streptococcal carriage. The empiric use of rifampin in combination with penicillin or erythromycin in nine of nine patients with streptococcal-associated psoriasis appeared to coincide with a marked improvement in their skin.
Subject(s)
Carrier State/drug therapy , Erythromycin/therapeutic use , Penicillin V/therapeutic use , Psoriasis/drug therapy , Rifampin/therapeutic use , Skin Diseases, Infectious/drug therapy , Streptococcal Infections/drug therapy , Adult , Child , Child, Preschool , Drug Therapy, Combination , Female , Humans , Male , Psoriasis/complications , Skin Diseases, Infectious/complications , Streptococcal Infections/complicationsSubject(s)
Nystatin/therapeutic use , Psoriasis/drug therapy , Adult , Aged , Humans , Male , Middle AgedABSTRACT
Twenty-eight patients with severe cutaneous infections received cefoperazone, 2 grams intramuscularly twice a day for seven days. A wide range of gram-positive and gram-negative pathogens were isolated from admission cultures. All patients showed rapid clinical improvement. Two patients did not complete the full course of therapy because of intervening medical problems unrelated to the antibiotic. No significant side effects were noted. Relapses or reinfections occurred in two patients. In conclusions, cefoperazone is a safe and effective antibiotic for use in skin infections requiring parenteral therapy.
